Pfizer, Inc. (NYSE:PFE) EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.67% and a net margin of 18.69%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the company earned $0.61 EPS.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.65%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 79.01%.

ILLEGAL ACTIVITY NOTICE: “Pfizer, Inc. (PFE) EVP Alexander R. Mackenzie Sells 7,350 Shares” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/02/pfizer-inc-pfe-evp-alexander-r-mackenzie-sells-7350-shares.html.

Several analysts have recently commented on the stock. J P Morgan Chase & Co set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday. Jefferies Group LLC set a $39.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday. Goldman Sachs Group, Inc. (The) set a $36.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday. UBS AG set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday. Finally, Berenberg Bank set a $36.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday. Two analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $38.35.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. City Holding Co. grew its holdings in Pfizer by 3.8% during the 1st quarter. City Holding Co. now owns 67,575 shares of the biopharmaceutical company’s stock valued at $2,311,000 after buying an additional 2,476 shares in the last quarter. Huntington National Bank grew its holdings in Pfizer by 6.2% during the 1st quarter. Huntington National Bank now owns 1,838,473 shares of the biopharmaceutical company’s stock valued at $62,894,000 after buying an additional 107,086 shares in the last quarter. Rothschild Investment Corp IL grew its holdings in Pfizer by 1.4% during the 1st quarter. Rothschild Investment Corp IL now owns 294,838 shares of the biopharmaceutical company’s stock valued at $10,086,000 after buying an additional 4,137 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in Pfizer by 1.2% during the 1st quarter. State of Alaska Department of Revenue now owns 481,359 shares of the biopharmaceutical company’s stock valued at $16,466,000 after buying an additional 5,539 shares in the last quarter. Finally, Hexavest Inc. grew its holdings in Pfizer by 5.2% during the 1st quarter. Hexavest Inc. now owns 6,873,339 shares of the biopharmaceutical company’s stock valued at $235,137,000 after buying an additional 337,987 shares in the last quarter. 69.01% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Insider Buying and Selling by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.